Analisis Efektivitas Biaya Penggunaan Kombinasi Doksetaksel Doksorubisin dan Kombinasi Siklofosfamid - Doksorubisin pada Pasien Kanker Payudara Stadium II di RSUD X Bungo Tahun 2022
Abstract
Breast cancer is cancer that occurs in the mammary glands due to cell malignancy or uncontrolled growth of cells from the gland cells and their ducts.Cancer treatment has consumed BPJS funding of approximately 7.6 trillion rupiah at 2019 – 2020 years. This study is needed to determine the ratio of treatment effectiveness and the average cost comparison of the drug combinations Doxetaxel-Doxorubicin and Cyclophosphamide-Doxorubicin at X Bungo General Hospital in 2022. Cost Effectiveness Analysis Method (Cost Effectiveness Analysis) is an analysis by looking at the effectiveness of treatment seen from medical record information and calculating the value of ACER and ICER.The object of this study is the Regional General Hospital (RSUD) in Bungo Regency. It is known that the component of direct medical costs is in the form of BPJS payments. Based on the ACER value, it shows that Cyclophosphamide - Doxorubicin has a lower ACER value than the ACER value for Doxetaxel - Doxorubicin. It can be concluded that Cyclophosphamide - Doxorubicin has a cost-effectiveness value, namely cost-effective and effective therapy compared to Doxetaxel - Doxorubicin.
Keywords
Full Text:
PDFReferences
Anita, & Sukamti. 2016. Pengaruh Pemberian Booklet Kemoterapi Terhadap Kemampuan Perawatan Diri Penderita Kanker Payudara Pasca Kemoterapi di Ruang Bedah Rumah Sakit Abdul Moeloek (RSAM) Bandar Lampung. Jurnal Kesehatan, Jurusan Keperawatan Poltekkes Tanjungkarang, 7(1), 26-33.
Depkes RI. 2009. Klasifikasi umur menurut kategori. Jakarta: Ditjen Yankes.
Hidayat, C.W. Suhartono. Dharminto. 2016. Jurnal Kesehatan Masyarakat, 4(3)
Kelvin J. F. dan Tyson, L. B. 2011. 100 Tanya-Jawab Mengenai Gejala Kanker dan Efek Samping Pengobatan Kanker. Jakarta : PT-Indeks.
Kementerian Kesehatan RI. 2022, Kanker Payudara Paling Banyak di Indonesia Kemenkes Targetkan Pemerataan Layanan Kesehatan. Go Kemkes, 1–1.
Mubarak, W.I. 2007. Promosi Kesehatan. Yogyakarta: Graha Ilmu
Nadia Farhanah Syafhan, Agusdini Banun Saptaningsih, Mutiara Jeany Rahayu Pertiwi, 2016, Analisis Cost-Effectiveness Seftazidim Generik pada Pasien Kanker Payudara di Rumah Sakit Kanker “Dharmais†Jakarta, 2012, Indonesia Journal of Cancer, 10(3), 113-119
Rahmawatie, E., & Adib Al Karomi, M. 2018. Edusainstek Sistem Pendukung Keputusan Deteksi Penyakit Kanker Payudara Menggunakan Algoritma Naive Bayes. Seminar Nasional
Rahmatya, Aisha dkk. 2015. Hubungan Usia dengan Gambaran Klinikopatologi Kanker Payudara di Bagian Bedah RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas.
Soviyati, E., Gani Utari, T.S. & Nabila, P. 2020, Determinan Kejadian Kanker Payudara di RSUD 45 Kuningan Periode Tahun 2018-2019, Jurnal Ilmu Kesehatan Bhakti Husada, 11(1), 62– 70
Sulviana, Erlinda Rara, And Lia Kurniasari. 2021. Hubungan Antara Usia, Pendidikan, dan Pekerjaan dengan Kejadian Kanker Payudara Pada Wanita di Kalimantan Timur. Borneo Student Research, 2(3) 1937–1943.
Syamsuryanita., 2020, Faktor yang Mempengaruhi wanita menopause dengan Kejadian Kanker Payudara di RSUD Syekh Yusuf Gowa, Jurnal Ilmiah Kesehatan Diagnosis, 15(3), 270–276.
The Global Cancer Observatory (Globocan). 2020. Indonesia. Diakses melalui https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
DOI: http://dx.doi.org/10.33087/jiubj.v24i1.4959
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
|
